Net Loss Per Share (Details) (USD $) In Millions, except Share data, unless otherwise specified	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Anti-dilutive securities
Potential common shares excluded from diluted net loss per share computation	68,426,292	70,067,756	68,179,100
Common stock issued in conversion of notes (in shares)	1,461,496		1,502,851
Stock options
Anti-dilutive securities
Potential common shares excluded from diluted net loss per share computation	21,816,611	21,996,579	20,107,923
4.75% Senior Notes
Anti-dilutive securities
Interest rate of debt (as a percent)	4.75%	4.75%	4.75%
Potential common shares excluded from diluted net loss per share computation	45,584,040	45,584,040	45,584,040
Pfizer Note due 2013
Anti-dilutive securities
Potential common shares excluded from diluted net loss per share computation		1,461,496	1,461,496
Aggregate principal amount of notes to be converted	10.0
Pfizer Note due 2014
Anti-dilutive securities
Potential common shares excluded from diluted net loss per share computation	1,025,641	1,025,641	1,025,641